[HTML][HTML] Lorlatinib for previously treated ALK-positive advanced NSCLC: primary efficacy and safety from a phase 2 study in People's Republic of China
S Lu, Q Zhou, X Liu, Y Du, Y Fan, Y Cheng… - Journal of Thoracic …, 2022 - Elsevier
Introduction Lorlatinib was found to have activity in ALK-positive NSCLC in a global phase 1
and 2 study. We report an ongoing phase 2 study in Chinese patients with ALK-positive …
and 2 study. We report an ongoing phase 2 study in Chinese patients with ALK-positive …
[HTML][HTML] Case report: a pregnant woman diagnosed as ALK-rearrangement lung large cell neuroendocrine cancer with brain metastasis
Z Fu, G Zhu, L Wang, S Hu, L Cheng, F Liu - Frontiers in Oncology, 2022 - frontiersin.org
Concomitant malignant tumors and pregnancy present many difficult questions to both
clinicians and patients. Due to no specific guidelines, each aspect of clinical management …
clinicians and patients. Due to no specific guidelines, each aspect of clinical management …
[HTML][HTML] The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer
SR Vitale, K Ruigrok-Ritstier, AM Timmermans… - BMC cancer, 2022 - Springer
Background In breast cancer (BC), recurrent fusion genes of estrogen receptor alpha
(ESR1) and AKAP12, ARMT1 and CCDC170 have been reported. In these gene fusions the …
(ESR1) and AKAP12, ARMT1 and CCDC170 have been reported. In these gene fusions the …
Novel TENM3–ALK fusion is an alternate mechanism for ALK activation in neuroblastoma
M Hiwatari, M Seki, R Matsuno, K Yoshida… - Oncogene, 2022 - nature.com
The identification of molecular events underlying the pathogenesis of neuroblastoma can
likely result in improved clinical outcomes for this disease. In this study, a translocation …
likely result in improved clinical outcomes for this disease. In this study, a translocation …
[HTML][HTML] Evaluating real world mutational differences between Hispanics and Asians in NSCLC at a large academic institution in Los Angeles
Introduction Hispanics living in the United States have higher rates of Epidermal Growth
Factor Receptor (EGFR) mutations compared with Non-Hispanic Whites. While this higher …
Factor Receptor (EGFR) mutations compared with Non-Hispanic Whites. While this higher …
Confirmation of lung adenocarcinoma as the primary cancer with detection of EML4-ALK rearrangement using next-generation sequencing: a case study
Y Mo, L Lin, J Zhang, Y Zhong, T Zhang… - … -Research and Practice, 2022 - Elsevier
We report a female patient, who presented as a carcinoma of unknown primary site with
multiple tumors in breast, lung, stomach, and ovary, was confirmed to be lung …
multiple tumors in breast, lung, stomach, and ovary, was confirmed to be lung …
Identification and anti-tumor evaluation of 3-acyl-indol-based 2, 4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant …
M Guo, H Wang, J Yang, X Wang, J Zhang, S Liu… - European Journal of …, 2022 - Elsevier
Abstract A series of novel 2, 4-diarylaminopyrimidine analogues (G-1∼ G-8 and I-1∼ I-24)
were rationally designed by incorporating 2-alkyl-3-acyl-1H-indol fragment to interact with …
were rationally designed by incorporating 2-alkyl-3-acyl-1H-indol fragment to interact with …
[HTML][HTML] Predictive role of neutropenia under crizotinib treatment in ALK-rearranged nonsmall cell lung cancer patients: A single-institution retrospective analysis
P Gürsoy, B Çakar, D Nart, E Göker - Indian Journal of Cancer, 2022 - journals.lww.com
Background: Anaplastic lymphoma kinase (ALK)-rearranged nonsmall cell lung cancer
(NSCLC) represents a molecular subgroup with high sensitivity to ALK inhibitors. Tyrosine …
(NSCLC) represents a molecular subgroup with high sensitivity to ALK inhibitors. Tyrosine …
[HTML][HTML] 阿法替尼治疗一例ALK 突变阳性肺鳞癌患者疗效分析
李伟 - Asian Case Reports in Oncology, 2022 - hanspub.org
探讨针对ALK 突变阳性肺鳞癌患者的肿瘤靶向治疗, 提高对其诊治水平. 报道一例ALK
突变阳性肺鳞癌及其靶向治疗, 同时对国内外报道的相关文献进行复习. 患者, 男, 54 岁 …
突变阳性肺鳞癌及其靶向治疗, 同时对国内外报道的相关文献进行复习. 患者, 男, 54 岁 …
Tỷ lệ đột biến gen EGFR và đột biến dung hợp gen EML4-ALK, ROS1 ở bệnh nhân ung thư phổi không tế bào nhỏ
HT Trần, H Lê - Tạp chí Y học Việt Nam, 2022 - tapchiyhocvietnam.vn
Tóm tắt Liệu pháp điều trị đích (LPĐTĐ) là một liệu pháp điều trị mới, đã được chứng minh
có hiệu quả cho bệnh ung thư phổi không tế bào nhỏ (UTPKTBN), đặc biệt trên nhóm bệnh …
có hiệu quả cho bệnh ung thư phổi không tế bào nhỏ (UTPKTBN), đặc biệt trên nhóm bệnh …